Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-04-11
2006-04-11
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C435S320100, C435S235100, C435S455000, C435S456000, C435S093000
Reexamination Certificate
active
07025967
ABSTRACT:
The present invention relates novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.
REFERENCES:
patent: 3962424 (1976-06-01), Zygraich et al.
patent: 4510245 (1985-04-01), Cousens et al.
patent: 4920209 (1990-04-01), Davis et al.
patent: 5024939 (1991-06-01), Gorman
patent: 5151267 (1992-09-01), Babiuk et al.
patent: 5756086 (1998-05-01), McClelland et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5820868 (1998-10-01), Mittal et al.
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5871727 (1999-02-01), Curiel
patent: 5922576 (1999-07-01), He et al.
patent: 6001591 (1999-12-01), Mittal et al.
patent: 6086890 (2000-07-01), Mittal et al.
patent: 6319716 (2001-11-01), Tikoo et al.
patent: 2002/0034519 (2002-03-01), Tikoo et al.
patent: 2002/0064859 (2002-05-01), Tikoo
patent: 2003/0099615 (2003-05-01), Tikoo
patent: 2003/0143200 (2003-07-01), Tikoo
patent: 2012895 (1990-09-01), None
patent: 0 185 573 (1986-06-01), None
patent: 0 259 149 (1988-03-01), None
patent: 0 389 286 (1990-09-01), None
patent: 2642767 (1990-08-01), None
patent: 2657880 (1991-08-01), None
patent: 0 185 573 (1986-06-01), None
patent: WO 86/06409 (1986-11-01), None
patent: WO 91/11525 (1991-08-01), None
patent: WO 95/16048 (1995-06-01), None
patent: WO 96/22398 (1996-07-01), None
patent: WO 98/59063 (1998-12-01), None
patent: WO 01/92547 (2001-12-01), None
patent: WO 02/06502 (2002-01-01), None
patent: WO 03/040305 (2003-05-01), None
Alley, C.D. and Mestecky, J. (1988). “The mucosal immune system” Chapter 9In B-lymphocytes in human diseases. G. Bird and J.E. Calvert, eds., Oxford University Press: Oxford, pp. 222-254.
Amalfitano, A. et al. (Apr. 1996). “Improved adenovirus packaging cell lines to support the growth of replication-defective gene-delivery vectors,”Proc. Natl. Acad. Sci.. USA, Genetics 93(8):3352-3356.
Andersson, M. et al. (1985). “Impaired Intracellular Transport of Class I MHC Angigens as a Possible Means for Adenoviruses to Evade Immune Surveillance,”Cell43:215-222.
Baca-Estrada, M.E. et al. (1996). “Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: Effect of antigen form on the induction of cellular and humoral immune responses,”Viral Immunol. 9(1):11-22.
Barbeau, D. et al. (1992). “Quantitative analysis of regions of adenovirus E1A products involved in interactions with cellular proteins,”Biochem. Cell .Biol. 70:1123-1134.
Bartha, A. (1969). “Proposal for subgrouping of bovine adenoviruses,”Acta. Vet. Acad. Sci. Hung. 19(3):319-321.
Baxi, M.K. et al. (1998). “Characterization of bovine adenovirus type 3 early region 2B,”Virus Genes 16(3):313-316.
Belák et al. (1986). “Subtypes of bovine adenovirus type 2 exhibit major differences in region E3,”Virology153:262-271.
Bellett, A.J.D. et al. (1989). “Functions of the Two Adenovirus Early E1A Proteins and Their Conserved Domains in Cell Cycle Alteration. Actin Reorganization. and Gene Activation in Rat Cells.”J. Virol. 63(1):303-310.
Benköet al. (1990). “Molecular Cloning and physical mapping of the DNA of bovine adenovirus serotype 4: study of the DNA homology among bovine, and porcine adenoviruses,”Journal of General Virology71:465-469.
Berg, J.M. (1986). “Potential Metal-Binding Domains in Nucleic Acid Binding Proteins,”Science232:485-487.
Berk, A. J. et al. (1979). “Pre-Early Adenovirus 5 Gene Product Regulates Synthesis of Early Viral Messenger RNAs,”Cell17:935-944.
Berk, A.J (1986). “Adenovirus Promoters and E1A Transactivation,”Ann. Rev. Genet20:45-79.
Berk, A.J. and Sharp, P.A. (1978). “Structure of the Adenovirus 2 Early mRNAs,”Cell. 14:695-711.
Berkner, K.L. (1989) “Development of Adenovirus Vectors for the Expression of Heterologous Genes”Biotechniques6:616-629.
Berkner, K.L. and Sharp, P.A. (1984). “Expression of dihydrofolate reductase, and of the adjacent Elb region, in an Ad5-dihydrofolate reductase recombinant virus,”Nuc. Acid Res. 12(4):1925-1941.
Bett, A.J. et al. (1993). “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,”J. Virol. 67(10):5911-5921.
Birnboim, H.C. and Doly, J. (1979). “A rapid alkaline extraction procedure for screening recombinant plasmid DNA,”Nuc. Acids Res. 7(6):1513-1523.
Boshart, M. et al. (Jun. 1985). “A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus,”Cell 41:521-530.
Bostock, C.J. (1990). “Viruses as Vectors”Vet. Microbiol. 23:55-71.
Boyle et al. (1992). “Vectors for Recombinant Vaccine Delivery”In Animal Parasite Conrol Utilizing Biotechnology, W.K. Yong CRC Press:Boca Raton, pp. 25-47.
Boyle et al. (1993). “Recombinant fowlpox virus vaccines for poultry,”Immunol. Cell Biol. 71:391-397.
Boyle, D.B. (1989). “How do other Poxviruses fit in as Potential Vectored Vaccine Substrates for Animal Immunizations?”Res. Virol. 140(5):483-491.
Branton, P.E. et al. (1985). “Transformation by Human Adenoviruses,”Biochim. Biophys. Acta780:67-94.
Brennan, S. and Savage, R. (1990). “Embryonic transcriptional activation of a Xenopus cytoskeletal actin gene does not require a serum response element,”Roux's Arch. Dev. Biol. 199:89-96.
Brough, D.E. et al. (Sep. 1996). “A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4,”J. of Virol. 70(9):6497-6501.
Bruder, J.T. and Hearing, P. (1989). “Nuclear Factor EF-1A Binds to the Adenovirus E1A Core Enhancer Element and to Other Transcriptional Control Regions,”Mol. Cell Biol. 9(11):5143-5153.
Burgert, H. and Kvist, S. (1985). “An Adenovirus Type 2 Glycoprotein Blocks Cell Surface Expression of Human Histocompatibility Class I Antigens,”Cell41:987-997.
Burgert, H. and Kvist, S. (1987). “The E3/19K protein of adenovirus type 2 binds to the domains of histocompatibility antigens required for CTL recognition,”EMBO J. 6(7):2019-2026.
Cai, F. et al. (1990). “Nucleotide and deduced amino acid sequence of the bovine adenovirus type 3 proteinse,”Nuc. Acids Res. 18(18):5568.
Carlin, C.R. et al. (1989). “Epidermal Growth Factor Receptor Is Down-Regulated by a 10,400 MW Protein Encoded by the E3 Region of Adenovirus,”Cell57:135-144.
Chanda, P.K. et al. (1990). “High Level Expression of the Envelope Glycoproteins of the Human Immunodeficiency Virus Type I in Presence of rev Gene Using Helper-Independent Adenovirus Type 7 Recombinants,”Virology175:535-547.
Chroboczek, J. and Jacrot, B. (1987). “The Sequence of Adenovirus Fiber: Similarities and Differences between Serotypes 2 and 5,”Virology. 161:549-554.
Chu, G. et al. (1987). “Electroporation for the efficient transfection of mammalian cells with DNA,”Nucl. Acids Res15(3):1311-1327.
Cladaras, C. and Wold, W.S.M. (1985). “DNA Sequence of the Early E3 Transcription Unit of Adenovirus 5,”Virology140:28-43.
Conley, M.E. et al., (1987). “Intravascular and mucosal immunoglobin A: Two separate but related systems of immune defense?”Ann. Intern. Med. 106:892-899.
Culp, J.S. et al. (1988). “The 289-amino acid E1A protein of adenovirus binds zinc in a region that is important
Babiuk Lorne A.
Graham Frank L.
Mittal Suresh K.
Prevec Ludvik
Morrison & Foerster / LLP
Mosher Mary E.
University of Saskatchewan
LandOfFree
Recombinant protein production in bovine adenovirus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant protein production in bovine adenovirus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant protein production in bovine adenovirus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3531674